Clinical Report: Impact of Pandemic Disruptions on HCC Monitoring

Overview

This study evaluates the impact of COVID-19 on hepatocellular carcinoma (HCC) surveillance among patients with cirrhosis in safety-net healthcare settings. Findings indicate a significant decline in surveillance rates during the pandemic, raising concerns about the long-term implications for patient outcomes.

Background

Hepatocellular carcinoma (HCC) is a major cause of cancer-related morbidity and mortality, particularly among patients with cirrhosis. Routine surveillance is crucial for early detection and improved outcomes, yet existing studies show suboptimal surveillance rates. The COVID-19 pandemic has further complicated care delivery, particularly in safety-net populations that already face barriers to timely healthcare.

Data Highlights

No numerical data available in the source material.

Key Findings

• Routine HCC surveillance is recommended every 6 months for patients with cirrhosis.
• A meta-analysis found only 24.0% of patients with cirrhosis received appropriate HCC surveillance.
• During the early pandemic, HCC surveillance rates dropped by 44% among veterans with cirrhosis.
• Safety-net populations experience significant barriers to accessing timely cirrhosis care.
• The study aims to assess whether HCC surveillance has returned to pre-pandemic levels in these vulnerable populations.

Clinical Implications

Healthcare providers should prioritize the resumption of routine HCC surveillance in safety-net populations to mitigate the impact of pandemic-related disruptions. Understanding the barriers faced by these patients is essential for improving care delivery and outcomes.

Conclusion

The disruptions caused by the COVID-19 pandemic have had a profound impact on HCC surveillance among patients with cirrhosis in safety-net settings. Ongoing efforts are needed to ensure these populations receive timely and effective monitoring.

Related Resources & Content

1. The Journal of Infectious Diseases, 2023 -- Impact of Pandemic-Induced Service Disruptions and Behavioral Changes on Hepatitis C Virus and HIV Transmission Amongst People Who Inject Drugs: A Modeling Study
2. The ASCO Post, 2022 -- COVID-19 Restrictions Linked to Delayed Breast Cancer Care at Safety-Net Hospital
3. The ASCO Post, 2020 -- Practical Approach to Management of Patients With Cancer During the COVID-19 Pandemic: An International Collaborative Group Statement
4. AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review - PubMed
5. Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis at US Safety-Net Health Systems - PubMed
6. Updates in Surgery — Management of Pancreatic Neuroendocrine Tumors through Surgery Amidst the COVID-19 Pandemic: Insights from a High-Volume Center's Retrospective Cohort Study
7. Multicenter evaluation of abbreviated MRI and ultrasound for detecting early-stage hepatocellular carcinoma
8. Hepatocellular Carcinoma Surveillance and Survival in a Contemporary Asia-Pacific Cohort | JAMA Network Open
9. AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review - PubMed
10. Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis at US Safety-Net Health Systems - PubMed
11. Cancer Screening 3 Years After the Onset of the COVID-19 Pandemic | Cancer Screening, Prevention, Control | JAMA | JAMA Network